Check out this Top Drugs of 2023 list with links to interesting reports in PharmaTell Studio. Contact us for a trial.

We've had Eyes On recent news further clarifying company restructures. In the midst of refining pipelines, and cutting corporate spending ..

We've been keeping Eyes On Deals & Raises in the BioPharma sector for the first quarter of 2024. Things seem to be heating-up ...

Lately we've been keeping Eyes On the corporate restructuring in the BioPharma sector. We've seen Big Pharma and BioTech refocusing ...

We've been trying to keep up with current events - here's some of what we've hay Eyes On this week.

Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...

This week we've had Eyes how BioPharma are bolstering their Portfolios for long-term success. From licensing assets ...

2024 is off to a busy start with M&A activities highlighted at the JP Morgan Healthcare Conference, plus another Genetic Medicines approval.

Following up on our previous post about Gene Therapies, we are sharing data on Genetic Medicines in development - pipelines, targets, dates

We've been keeping Eyes On the Gene Therapy area - and thought we would post some general information about the area ...

The news this week was full of "Ups-n-Downs." We've noted a few here and know there were more surprises with clinical data results, M&A, and

Some of this week's news includes Casgevy Approval, Novo's REDEFINE 4 Trial, , new Manufacturing plant and more.

While we've been curating 3Q23 Results reports, we've had eyes on drug approvals, Business Development activities, & even some patent ...

We found ourselves looking closer at the disease, the history of weight loss medications, and the potential impact of effective weight manag

This week we had Eyes On the upcoming IRA Drug pricing negotiations - here's some of the news and views we saw.

We have Eyes on Pharma Conferences this week. Don't forget to check PharmaTell Studio for the latests Planners, Insights, and Key Takes.

The MedTech sector seemed to take the brunt of the 2022 market decline but looking to forward there may be light at the end of the tunnel.

We’ve had Eyes On – Some of the Post Holiday /Pre-Earnings News Snippets As the companies and the markets gear up for Results, tucked in...

I've got Eyes On the Review / Preview Articles for the Healthcare Industry. It's interesting to see a snapshot of 2022 and some predictions

After all the quarterly results reporting, we've had eyes on product approvals, resubmissions, and a withdrawal.